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Human cardiovascular malformations (CVMs) frequently have a genetic contribution. 
Through the application of novel technologies, such as next-generation sequencing, 
DNA sequence variants associated with CVMs are being identified at a rapid pace. While 
clinicians are now able to offer testing with NGS gene panels or whole exome sequenc-
ing to any patient with a CVM, the interpretation of genetic variation remains problematic. 
Variable phenotypic expression, reduced penetrance, inconsistent phenotyping meth-
ods, and the lack of high-throughput functional testing of variants contribute to these 
challenges. This article elaborates critical issues that impact the decision to broadly 
implement clinical molecular genetic testing in CVMs. Major benefits of testing include 
establishing a genetic diagnosis, facilitating cost-effective screening of family members 
who may have subclinical disease, predicting recurrence risk in offsprings, enabling early 
diagnosis and anticipatory management of CV and non-CV disease phenotypes, pre-
dicting long-term outcomes, and facilitating the development of novel therapies aimed at 
disease improvement or prevention. Limitations include financial cost, psychosocial cost, 
and ambiguity of interpretation of results. Multiplex families and patients with syndromic 
features are two groups where disease causation could potentially be firmly established. 
However, these account for the minority of the overall CVM population, and there is 
increasing recognition that genotypes previously associated with syndromes also exist 
in patients who lack non-CV findings. In all circumstances, ongoing dialog between 
cardiologists and clinical geneticists will be needed to accurately interpret genetic testing 
and improve these patients’ health. This may be most effectively implemented by the 
creation and support of CV genetics services at centers committed to pursuing testing 
for patients.
Keywords: genetics, congenital heart disease, phenotyping, next-generation sequencing, phenomics, genomics, 
mutation
Abbreviations: CMA, chromosomal microarray analysis; CNV, copy number variant; CVM, cardiovascular malformation; 
HPO, Human Phenotype Ontology; IPCCC, International Pediatric and Congenital Cardiac Code; NGS, next-generation 
sequencing; VUS, variant of uncertain significance; WES, whole exome sequencing.
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iNTRODUCTiON
Cardiovascular malformations (CVMs) are the most common 
birth defects with an incidence estimated at approximately 
8/1000 live births (1). Taking into account very high rates of 
CVMs in spontaneous abortuses, common malformations, such 
as BAV [present in 1.3% of the population (2)], and latent cardiac 
diseases, such as aortic dilation, which are not included in the 
birth incidence of CVMs, genetically mediated CVMs are likely 
much more common than previously thought. When consider-
ing the etiology of CVMs, as opposed to the proportion of CVM 
cases that manifest as disease at birth, the incidence increases to 
approximately 5% (1). The common nature of these birth defects, 
combined with their heterogeneous etiologies, makes genetic 
evaluation both important and complex.
The underlying causes of CVMs are varied and can include 
cytogenetic abnormalities, single gene disorders, epigenetic 
alterations, environmental etiologies, or most commonly, 
multifactorial etiologies. Chromosomal abnormalities account 
for 12–14% of all live-born cases and 20–33% of fetal cases 
(1, 3–5). CVMs can occur as isolated findings, as part of a 
well-defined syndrome, or in conjunction with additional ext-
racardiac anomalies not formally recognized as a syndrome (6). 
The American Heart Association has summarized reasons for 
establishing a genetic diagnosis for cardiac conditions (7). The 
benefits of a genetic diagnosis include improved longitudinal and 
acute medical management (8). In addition, a genetic diagnosis 
allows for the provision of anticipatory guidance, risk stratifica-
tion for family members, and recurrence risk information (7). 
Despite an increasing awareness of the genetic basis of CVMs 
and the clinical importance of making an accurate diagnosis, 
there remain many questions about the best approach to clinical 
application of molecular or cytogenetic testing in individuals 
with a CVM.
Recently, we summarized the overall progress in the molecu-
lar genetic analyses of CVMs and current recommendations 
for clinical application of genetic testing (9). In particular, we 
reviewed the utility and limitations of chromosomal microarray 
analysis (CMA) and the emerging clinical roles for whole exome 
sequencing (WES) and other NGS technologies for CVMs. Here, 
we focus on the opportunities and challenges of clinical NGS 
testing and highlight the importance of phenotyping to improve 
clinical genetic testing interpretation and to drive etiology-
centered research. NGS technologies generate abundant amounts 
of precise human genetic data, but imprecise phenotype data 
limit the power to determine genotype–phenotype correlation 
(10). We propose that deep phenotyping of CVMs and existing 
phenomic analysis methods provide major opportunities for 
progress analogous to the recently realized efforts in genomics 
and developmental biology. The integration of genetic findings 
with deep phenotyping will improve our understanding of disease 
etiology and advance medical care.
ePiDeMiOLOGY OF CvMs
Cardiovascular malformations represent the single largest cause 
of infant mortality resulting from birth defects (4). Approximately 
25% of infants with CVMs are thought to have syndromic con-
ditions based on the findings of multiple congenital anomalies 
or neurodevelopmental delays (11). The distinction between 
syndromic and non-syndromic, or isolated, CVMs can be subtle, 
and criteria to differentiate these categories are inconsistent 
between studies. In addition, as genetic diagnostic modalities 
have become more sophisticated, the spectrum of genetic syndro-
mic conditions has expanded, and therefore earlier assessment of 
syndromic cases may represent an underestimate.
The high heritability of CVMs provides evidence for an 
important genetic role in these birth defects. Specific CVMs 
show strong familial clustering in first-degree relatives, ranging 
from 3- to 80-fold compared to the prevalence in the popula-
tion (12). Heritability for some types of CVMs is as high as 
70–90%, indicating the strong genetic contribution (13–15). 
Not all families show evidence of similar types of CVMs, and 
familial clustering of discordant CVMs has also been docu-
mented (16). Because CVMs are so common, the majority of 
cases occur in individuals without a family history of CVMs 
despite a high heritability. The prevalence of familial CVM will 
likely increase as more patients with CVMs survive into adult-
hood. Epidemiologic studies may underestimate the number of 
familial cases due to the high rate of miscarriages of fetuses with 
CVMs and reproductive decisions to limit future pregnancies in 
families with a child with a CVM.
The sibling or offspring recurrence risk across all types of 
CVMs is estimated at 1–4%. This empiric recurrence risk sug-
gests that the majority of CVMs have a multifactorial etiology 
(17, 18). These estimates represent an average of different risks 
across the population and include individuals with higher recur-
rence risks due to Mendelian inheritance as well as individuals 
with lower risks due to a de novo event in the affected individual 
or a teratogenic etiology. Empiric recurrence risks for specific 
types of CVMs, such as left ventricular outflow tract obstructive 
defects, are higher. While the incidence of CVMs appear to be 
similar in most populations, there are some specific types of 
CVM that show important differences (14, 19, 20). In addition, 
there is an increased rate of CVMs in populations with increased 
consanguinity, often attributed to autosomal recessive mutations 
in disease genes (21–25). Family history of CVMs is one of the 
most consistently identified risk factors for identifying a CVM 
prenatally.
THe GeNeTiC BASiS OF CvMs
Cardiovascular malformations can be subdivided into syn-
dromic and non-syndromic cases. Aneuploidies (disorders of 
chromosome number) are frequent causes of syndromic CVMs. 
As genetic testing technologies have evolved, CMA has emerged 
as a test with higher resolution and increased sensitivity over 
routine chromosome analysis (i.e., karyotype) for detecting 
abnormalities. Submicroscopic chromosome deletions and dupli-
cations [also known as copy number variants (CNVs)] underlie 
many genetic syndromes, and the term genomic disorder is 
used to refer to these conditions. Gene dosage is an important 
concept underlying CVMs. For many genes, a missing (deletion) 
or extra (duplication) copy of that gene results in no phenotypic 
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consequences. In contrast, dosage-sensitive genes produce 
abnormal phenotypes in the absence of two functional genes. 
22q11.2 deletion syndrome and Williams–Beuren syndrome are 
two examples of genomic disorders that are commonly associated 
with CVMs related to dosage-sensitive genes (TBX1 and ELN, 
respectively). Variants within TBX1 and ELN are associated with 
CVMs in non-syndromic patients (26, 27). This fact illustrates 
an important principle: understanding the genetic basis for syn-
dromic CVMs can identify genes responsible for non-syndromic 
isolated CVMs.
Because of the increased yield with CMA, it should be the first-
line test for genetic analysis in infants with CVMs except in cases 
that are classic aneuploidies (9). CMA is considered standard 
of care testing for individuals with developmental disability or 
multiple congenital anomalies, and it has been shown to be cost-
effective (28, 29). Importantly, CNVs have emerged as important 
causes of both syndromic and non-syndromic CVMs, occurring 
in approximately 3–25% of syndromic cases and 3–10% of non-
syndromic cases (6, 30).
In addition to aneuploidies, chromosome rearrangements, 
and CNVs as causes of CVMs, mutations at the nucleotide level 
are also important genetic causes. These mutations are often 
inherited in a Mendelian fashion, and autosomal dominant, 
autosomal recessive, and X-linked inheritance patterns have been 
documented for both syndromic and non-syndromic CVMs 
(31–33). For dominantly inherited conditions, such as Noonan 
or Holt–Oram syndromes, individual recurrence risks for off-
spring with the syndrome is 50%. Importantly, not all patients 
with a particular syndrome have associated heart defects, and the 
proportion can vary by syndrome. Furthermore, the presence or 
severity of a CVM in the parent does not predict the severity in 
the child.
The genetic architecture of CVMs suggests that a majority 
of non-syndromic cases result from multifactorial causes and 
behave as a complex trait. Similar to other conditions inherited 
as a complex trait, isolated CVMs may show familial clustering 
with reduced penetrance. Nevertheless, Mendelian inheritance 
does occur, albeit less frequently, and de novo mutations are 
another important cause (34, 35). The distinction between 
monogenic and complex traits can be overly simplistic, as is 
drawing a distinct boundary between syndromic and non-
syndromic causes. Indeed, variants in genes known to cause 
syndromic forms of CVMs are now identified in non-syndromic 
cases. In addition, traits that appear to be monogenic can be 
influenced by variation in multiple genes, termed modifier 
genes. The reverse is also true: complex traits can be predomi-
nantly influenced by variation in a single gene. These findings 
likely explain the decreased penetrance and variable expressivity 
that are so common among both syndromic and non-syndromic 
CVMs. Currently, there remain many unknowns about the 
contribution of common variants, rare variants, CNVs, de 
novo mutations, epigenetics, and environmental exposures to 
the development of CVMs. For these reasons, recurrence risks 
for apparently isolated CVMs can be difficult to assign, and 
even in cases of Mendelian inheritance, decreased penetrance 
and variable expressivity present dilemmas to predicting genetic 
effect on phenotype. There is need for a systematic approach to 
accurate and detailed phenotyping in order to begin character-
izing these complexities. In addition, these factors are important 
considerations when contemplating molecular genetic testing in 
the CVM population.
In an effort to better understand genetic causes of CVMs, 
systems biology approaches have been used to assess functional 
convergence of causative CVM genes, effectively combining 
knowledge of genetics and developmental biology. Interestingly, 
these approaches have suggested that different CVM risk factors 
are more likely to act on distinct components of a common func-
tional network than to directly converge on a single genetic or 
molecular target (36, 37). Developmental pathways acting inde-
pendently or coordinately contribute to heart development and 
have been the subject of recent reviews (38, 39). These pathways 
often exhibit extensive cross talk, and a particular signal can be 
antithetically regulated at different developmental time points. 
Systems biology suggests a highly complex milieu in which 
individual or multiple genetic variants could potentially act to 
disrupt normal heart morphogenesis. The web of interactions 
of signaling and transcriptional networks highlighted by these 
approaches hint at the possibility that some CVMs may result 
from additive effects of multiple low-effect susceptibility alleles. 
The integration of genetic analysis with developmental biology 
knowledge provides a powerful platform for variant interpreta-
tion and candidate gene identification, but expanded databases 
and prediction methods are needed. Improving the assimilation 
of this information with careful cardiac phenotyping from human 
studies represents an opportunity to advance our understanding 
of the etiology of specific CVMs.
SeQUeNCeD-BASeD APPROACHeS 
TO THe GeNeTiCS OF CvMs
The importance of CNV analysis in both syndromic and non-
syndromic CVMs has been documented (6, 9, 40–44). Genetic 
testing in infants with CVMs is frequently underutilized but 
indicated in all infants with complex CVMs, except in cases war-
ranting syndrome-specific testing (9, 45, 46). Decisions about 
additional genetic testing after CMA are less straightforward. The 
increased sophistication of genetic testing technology provides 
the ability to interrogate an ever increasing array of genes to 
identify the molecular basis of disease. Distinguishing testing 
that has clinical utility is necessary, but few evidence-based 
guidelines exist, in part, because of difficulties with phenotyping. 
As a result, clinical experience is the primary criterion utilized 
in deciding on genetic testing, and substantial practice variation 
exists for CVMs.
With the development of NGS, large gene sequencing panels 
have become both technically feasible and cost-effective. As a 
result, NGS panels for CVMs are developing rapidly. For exam-
ple, genetic testing for Noonan syndrome has been available for 
several years, with additional genes being added to NGS panels 
as they are identified. The current yield of testing using NGS 
Noonan syndrome panels in suspected cases is approximately 
70–85%. As another example, testing for heterotaxy syndrome, 
situs inversus, and primary ciliary dyskinesia are combined into 
one NGS panel available from several commercial laboratories.
4Landis and Ware Genetic Testing in Cardiovascular Malformations
Frontiers in Cardiovascular Medicine | www.frontiersin.org July 2016 | Volume 3 | Article 22
Several studies have also documented the utility of NGS panels 
in diagnostic evaluation of CVMs in non-syndromic multiplex 
families. Blue et  al. used a custom NGS panel consisting of 57 
genes known to cause CVMs to sequence 16 probands from mul-
tiplex families (47). After identifying potential disease-causing 
variants with the panel in probands, affected family members 
were tested to confirm segregation with disease. Five variants in 4 
genes, TBX5, TFAB2B, ELN, and NOTCH1, were concluded to be 
likely disease-causing among the 16 families, giving a diagnostic 
yield of 31%. A similar study by Jia et al. utilized a slightly differ-
ent 57 gene panel in 13 multiplex non-syndromic families (48). 
Altogether, 44 rare variants were identified. After bioinformatics 
predictions and testing for segregation in other family members, 
a likely disease-causing variant was established in 6 of 13 families, 
giving a diagnostic yield of 46%. The causative genes identified 
in this study (NOTCH1, TBX5, and MYH6) partially overlapped 
those of Blue et  al. Finally, in a recent study using a panel of 
97 genes in 78 unrelated probands with bicuspic aortic valve, 
33 potential disease-causing rare variants were identified (49). 
However, these variants were identified in only 16 of the subjects, 
indicating that many carried more than one potential disease-
causing variant. Because all but two variants were inherited from 
an unaffected family member, the clinical interpretation of the 
pathogenicity is difficult. Together, these cases highlight benefits 
and limitations of NGS panels in non-syndromic patients. First, 
a substantial number of rare variants will be identified even with 
relatively small panels. Second, diagnostic yield is high in multi-
plex families, especially when family members are available for 
follow-up testing of variant segregation with disease. However, 
in isolated cases, our current approaches for variant classification 
and functional prediction make clinical interpretation difficult. 
Third, careful phenotyping is critical, and distinction of syn-
dromic versus non-syndromic isolated disease is often difficult 
even in multiplex families. For example, mutations in TBX5 
causes Holt–Oram syndrome, which is characterized by upper 
limb defects that are highly variable but thought to be completely 
penetrant with careful examination. In the study by Blue et  al. 
(47), the authors note that subtle hand anomalies may have been 
missed because radiologic examination was not performed in 
either family. Finally, while segregation with disease provides 
strong evidence for pathogenicity of variants, the reduced pen-
etrance of many CVMs suggests that a variant inherited from an 
unaffected parent does not necessarily rule out disease causation 
or susceptibility.
Large gene panels have the advantage of increasing the sensitiv-
ity of the test, but they also increase the likelihood of identifying 
variants of uncertain significance (VUS). These increase in direct 
proportion to the number of genes tested, increasing the com-
plexity of the interpretation and genetic counseling. Importantly, 
the strength of evidence for disease causality for genes on current 
panels differs. Some well-established disease-causing genes have 
a wealth of information about variants, but genes more recently 
implicated in disease may have much less information available. 
The latter situation increases the likelihood of finding a VUS. In 
all cases, it is important for patients to understand that a negative 
genetic test result does not rule out a genetic cause. The compo-
sition of gene panels varies by testing lab. It is critical that the 
ordering physician understands these factors to order the most 
appropriate test.
Whole exome sequencing interrogates the coding regions of 
every gene using an NGS approach. First offered as a clinical 
genetic test in 2011, the clinical scenarios in which WES is uti-
lized continue to expand. For less than twice the cost of most large 
targeted gene panels, WES provides sequence data for all known 
genes, making it comparatively cost-effective. It can be superior to 
targeted panels for rare syndromes with CVMs in which a genetic 
cause is suspected but the differential diagnosis is challenging. 
WES has also been shown to be effective in multiplex families 
with CVMs. Large, multiplex families with concordant CVMs are 
good candidates for identifying monogenic disease variants. In 
addition, recently, a large multiplex family with discordant CVMs 
across four generations was studied by WES followed by targeted 
sequencing of candidates (50). A missense variant in MYH6 was 
identified in 10 of 11 affected family members and absent in 10 
unaffected family members. An additional four unaffected family 
members also carried the variant. This study not only illustrates 
the utility of WES for large families but also highlights the com-
plexity of analysis and the challenges that variable expressivity 
and non-penetrance pose for conclusive interpretation of causal-
ity when variants are identified.
Interpretation of causality of a rare variant in a candidate gene 
is theoretically simplified when the variant occurs de novo in the 
proband. In these cases, the variant is frequently interpreted as 
likely disease-causing. Therefore, in clinical WES, parental samples 
are typically requested, if available, in order to aid interpretation. 
The multisite research study by the Pediatric Cardiac Genomics 
Consortium provides insight into the frequency of de novo vari-
ants that are likely disease-causing in a large CVMs cohort (34). 
Using a trio design to study 362 non-syndromic probands with 
CVMs, including conotruncal defects, left ventricular outflow 
defects, and heterotaxy, 249 protein-altering de novo variants 
were identified. Compared with control trios, CVM probands had 
more de novo variants in genes highly expressed during cardiac 
development and more de novo variants with likely damaging 
effects. The variants were enriched for methylation pathways 
and were thought to explain approximately 10% of CVMs in the 
cohort. In a follow-up study of this cohort in which 1213 trios 
were studied, more de novo variants were identified in cases as 
compared to controls (35). Interestingly, many of these variants 
were identified in genes known to be important for heart develop-
ment, and approximately one-third were in genes known to cause 
syndromic CVMs. Furthermore, there was a striking overlap of 
variants in genes previously associated with neurodevelopmental 
delay. These findings may have important clinical impact not only 
for guiding genetic testing but also for identifying individuals 
with CVMs who are at increased risk for neurodevelopmental 
disability and for implementing early intervention.
Limitations to WES in clinical practice include the high likeli-
hood of identifying VUSs, the decreased depth of sequencing 
as compared to targeted panels, and the increased likelihood 
of identifying a mutation for a disease unrelated to the clinical 
presentation or reason for performing the genetic testing. The 
latter situation mandates pretest genetic counseling to discuss 
the possibility of secondary or incidental findings. At this time, 
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WES may be the test of choice for syndromic CVMs in which 
the syndrome is not recognized. It should be considered for 
both syndromic and apparently non-syndromic CVMs that are 
inherited in a Mendelian fashion, particularly if the differential is 
broad or would require multiple targeted panels to test. WES in 
cases of isolated, non-syndromic CVMs is more controversial due 
to interpretation ambiguity and financial cost of testing. However, 
recent data indicate that the incidence of disease-causing de novo 
mutations is high and should prompt consideration of WES 
especially when parents are available for testing (34, 35).
THe iMPORTANCe OF PHeNOTYPiNG
As high-throughput technologies, such as NGS, have developed 
and spread, the volume of genetic data available in clinical and 
research databases has amassed very quickly. These molecular 
data are mostly considered to be highly accurate. Accordingly, it 
is critical that equally accurate phenotype information be used 
for interpretation of genetic variants. However, the progress in 
molecular and bioinformatics techniques has vastly outpaced 
methods to collect and organize detailed and accurate pheno-
type data across the spectrum of human health and disease (51). 
Unfortunately, phenotype information associated with genetic 
diagnoses has not historically been collected and/or reported 
in a consistent manner. Thus, there is now a pressing need to 
improve phenotyping practices. The field of phenomics has 
emerged to address this need, consisting of (1) detailed and 
accurate phenotype data collection, termed deep phenotyping 
and (2) computational phenomic analysis (10, 52, 53). With 
the proper motivation and resources, there is a tortuous but 
passable route to implement a deep phenotyping approach for 
clinical testing and etiologic research of CVMs. The following 
sections describe the current status of phenotype data collection 
and analysis across the spectrum of human disease, review the 
current phenotype classification systems commonly used in 
the clinical care and research of CVMs, highlight the current 
phenotyping challenges in clinical CVM genetic testing, and 
emphasize the critical need to harmonize existing phenotype 
data to advance the field.
DATABASe APPROACHeS TO DeeP 
PHeNOTYPiNG
Deep phenotyping has been defined as “the precise and compre-
hensive analysis of phenotypic abnormalities in which the indi-
vidual components of the phenotype are observed and described” 
(10). Because there are virtually unlimited ways to describe the 
phenotype of a patient in the clinical setting, there needs to be 
a constrained language or set of phenotype definitions to apply 
systematically in order to analyze differences and similarities 
between patients. An example of this problem of phenotype 
unboundedness exists in the Online Mendelian Inheritance 
in Man database (http://omim.org/), where manually curated 
phenotype data are highly detailed but unconstrained (54). An 
ontology is one approach used to organize phenotype data into a 
structure that is robust for computational analysis. An ontology 
consists of a set of definitions (or terms) that are assembled as 
a directed acyclic graph. A number of biomedical ontologies 
have been developed, including the Gene Ontology, Disease 
Ontology, Mammalian Phenotype Ontology, and the Human 
Phenotype Ontology (HPO) (55–58). The HPO is a manually 
curated ontology that was first developed in 2007 and has since 
grown to include more than 10,000 terms (each term represents 
a phenotype definition) (58). The HPO is hierarchically ordered 
so that the terms at the highest level of the graph consist of the 
broadest phenotypes. Each term is subdivided into more specific 
subclass phenotypes until reaching the lowest tier consisting 
of the most detailed and specific phenotypes. In the HPO, a 
phenotype term “points” (as a unidirectional edge) to each of its 
phenotype superclass terms.
In recent years, the HPO has become a heavily used system 
for phenotyping in the field of human genetics. For instance, the 
International Standards for Cytogenomic Arrays Consortium 
was among the first large-scale genotype–phenotype initiatives 
to adopt the HPO system and demonstrate effectiveness (59). 
This consortium subsequently became the basis for the Clinical 
Genome Resource (ClinGen), sponsored by the National 
Institutes of Health. ClinGen aims to facilitate and establish 
standards for large collaborative efforts to make genotype–phe-
notype discoveries and implement these discoveries clinically 
(60). ClinGen utilizes a public database, ClinVar, as the primary 
repository of variant and phenotype data. The data are compiled 
from diverse sources, including domain-specific databases, 
clinical and research molecular laboratories, clinical provid-
ers, and others (61). Similar to the International Standards for 
Cytogenomic Arrays Consortium, ClinVar utilizes the HPO to 
define phenotypes and structure data. A number of other data-
bases containing genotype–phenotype data, such as DECIPHER 
and PhenomeCentral, also utilize the HPO (62, 63).
Whereas the usage of the HPO has increased among genetics 
providers and investigators, there are many alternative phenotype 
classification systems in practice. Most of these systems, such as 
the 10th revision of the International Statistical Classification 
of Diseases and Related Health Problems (ICD-10), are not 
designed for the purpose of genetic discovery. Thus, in order to 
explore genotype–phenotype relationships leveraging separate 
data sets that potentially contain valuable phenotype informa-
tion, it is necessary to cross-link systems by mapping phenotypes. 
These mappings have been created for a number of data sets, but 
harmonizing databases with different language definitions and 
structures presents significant challenges and limitations (54). 
At the very least, the HPO illustrates the motivation and value 
of establishing a standardized language for deep phenotyping. 
Importantly, there are user-friendly software applications, such 
as Phenotips, that enable HPO format data entry (64). Thus, the 
HPO represents a promising system for phenotyping CVMs in 
clinical and research settings that would align with many major 
genotype–phenotype efforts across human disease.
CvM NOMeNCLATURe AND 
CLASSiFiCATiON MeTHODS
Abbott published the first classification method of CVM 
phenotypes in the Atlas of Congenital Cardiac Disease in 1936 
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(65). Since then, the precision and accuracy of diagnostic 
modalities, such as echocardiography and cardiac magnetic 
resonance imaging, as well as understanding of the morphologi-
cal and molecular aspects of CV development, have advanced 
significantly. This has naturally led to the adoption of newer 
CVM phenotype nomenclatures and classification systems over 
time. In addition, different practical needs, such as health-care 
billing, clinical outcomes research, and epidemiology, have given 
rise to a heterogeneous set of CVM classification systems. One 
example is the International Pediatric and Congenital Cardiac 
Code (IPCCC), which was created in 2005 by the International 
Nomenclature Committee for Pediatric and Congenital Heart 
Disease. This group includes experts in the fields of pediatric 
cardiology and cardiothoracic surgery (66). A stated goal of 
the IPCCC is to facilitate clinical outcomes research across 
medical centers. Another important CVM phenotyping sys-
tem, The Fyler Classification System, was created at Boston 
Children’s Hospital to facilitate local outcomes research and 
enhance inter-provider clinical communication (67). Since its 
creation roughly five decades ago, the “Fyler codes” have been 
expanded and are mapped to the IPCCC. Another frequently 
used classification system for outcomes research is implemented 
in the Society of Thoracic Surgeons’ National Congenital Heart 
Surgery Database (68). Finally, the Botto classification system 
was developed and tested using data from the National Birth 
Defects Prevention Study with the principal aim to investigate 
the etiology of CVMs using epidemiological data (69). Unique 
among other classification systems, the Botto system emphasized 
morphological and developmental concepts by grouping indi-
vidual CVMs into three hierarchical levels. With the recognition 
that different hypotheses and statistical approaches may require 
minimum group sizes to achieve adequate power, groupings 
were also partly based on the known frequency and distribu-
tion of individual CVM phenotypes (70). Taken together, there 
is a long precedent for organizing CVM phenotypes but lack 
of a consensus nomenclature system. Clinically, this lack of 
consensus creates barriers in communication with non-cardiac 
specialists and hinders the attempt to establish genotype–phe-
notype correlations. In research studies, this lack of consensus 
creates difficulties comparing results between studies utilizing 
different classification schemes.
OBSTACLeS TO DeeP PHeNOTYPiNG 
iN CvMs
The lack of a consensus nomenclature system for classifying 
CVMs can lead to significant confusion and obstacles to the 
goal of identifying genotype–phenotype relationships. Not 
only is there a lack of consensus on methods to group CVMs 
but also many CVMs have synonymous definitions that vary 
in use across, and in some cases within, clinical programs. For 
instance, there are at least six synonyms for the diagnosis of 
perimembranous ventricular septal defect, including infracris-
tal, conoventricular, membranous, paramembranous, and type 1 
(71, 72). Furthermore, not all CVMs encountered in patients will 
fit cleanly into commonly used CVM definitions. For example, 
a ventricular septal defect is typically defined by the anatomic 
location of the defect within the ventricular septum, but a defect 
extending across these anatomic boundaries is not uncommon 
(e.g., a perimembranous ventricular septal defect that extends 
into the muscular or inlet portions of the septum). These 
variations may be developmentally significant. Furthermore, a 
number of CVMs have morphological subtypes that are classi-
fied much differently between systems, such as the Collett and 
Edwards versus Van Praagh systems, to define subtypes of persis-
tent truncus arteriosus (73, 74). Distinguishing CVM subtypes 
may improve detection of single gene defects with NGS panels 
or WES. Taken together, the heterogeneity in routine clinical 
definition of CVMs is a major impetus for genotype–phenotype 
databases to utilize a controlled vocabulary structured to man-
age these intricacies.
There are additional obstacles to consider when organizing 
data or reports from different clinical programs. For instance, the 
standard operating procedures in pediatric cardiology imaging 
laboratories are not uniform across programs despite established 
recommendations (75). The level of detail provided in clinical 
reports, such as echocardiography findings, can be variable, and 
nomenclatures are variable between report-generating software 
(66). Many aspects of cardiac imaging interpretation depend 
upon qualitative judgment and experience of the reader, and 
diagnoses may change or resolve as the patient ages or follow-up 
studies are performed. Even in circumstances where quantifica-
tion is feasible, technically standardized, and clinically useful, 
such as measuring anatomic dimensions, there may be a lack 
of consensus normative reference databases of healthy children 
(76). For example, there at least five published normal data sets 
for calculating z-scores of aortic diameters in children (77). Our 
experience is that calculated z-scores range widely depending on 
the normal data set selected.
With the goal of deep phenotyping in mind, a complete 
study that includes documentation of negative findings is key 
to fully defining the patient’s phenotype. However, this may 
require multiple studies or even different imaging modalities. 
For instance, in some cases, it can be difficult to absolutely rule 
in or rule out the presence of extracardiac vascular anomalies, 
such as abnormal aortic arch sidedness or persistent left superior 
vena cava with transthoracic echocardiography. Subtle anomalies 
of coronary artery branching are very difficult to characterize 
with echocardiography and may not be rigorously interrogated 
if considered clinically insignificant. Whether these types of 
subclinical data would advance the understanding of genetics and 
developmental mechanisms is not known but is quite possible. 
Additionally, the patient’s age at the time of study may impact 
not only the technical quality but also the actual diagnoses. 
Cardiovascular hemodynamics begin to change from the time 
of birth, cardiac morphology may change as the child grows, and 
a complete diagnosis may not be reached until normal physi-
ological events, such as closure of the ductus arteriosus. In spite 
of all of these potential confounders and challenges, the fact that 
the clinical care of patients is absolutely dependent on accurately 
characterizing the patient’s phenotype promises to facilitate the 
implementation of deep phenotyping of CVMs.
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MAXiMiZiNG THe OPPORTUNiTieS FOR 
GeNOTYPe–PHeNOTYPe CORReLATiONS
In the field of genetics, there has been important progress in 
the analysis of phenotype data using computational techniques, 
sometimes referred to as phenomic analysis. Most phenomic 
analysis to date has consisted of algorithms used to prioritize 
lists of candidate disease-causing genes based on phenotype 
data. Gene prioritization algorithms are useful for interpreting 
variants identified with NGS techniques, such as clinical WES. 
The premise for these phenotype-based algorithms is to utilize 
“semantic similarity,” or the mathematical similarity between a 
given individual’s phenotype and the phenotypes of reference 
disease populations, such as those with established genetic dis-
orders. This similarity measure can then be used as the score for 
prioritizing which variants are most likely to contribute to the 
individual’s phenotype. Some prediction techniques exclusively 
utilize phenotype similarity algorithms (78, 79). Alternatively, 
phenotype-based scores are one component of multidimensional 
variant prioritization applications that combine algorithms 
using multiple features, such as the predicted effect of a variant 
on protein function (80). Variant prioritization applications 
that incorporate human phenotype data in this manner include 
Phevor, Phen-Gen, and Exomiser (81–83). There is evidence that 
incorporation of structured human phenotype data does improve 
performance (80). Importantly, computational algorithms based 
on semantic similarity to compare phenotypes across species have 
also been implemented in applications, such as Exomiser. There 
is ongoing work to advance phenotype-based computational 
methods. The accuracy of these methods is likely to improve as 
more deep phenotyping data are generated and shared.
With the goal of discovering genotype–phenotype relation-
ships for CVMs, the National Heart, Lung, and Blood Institute’s 
Bench to Bassinet program has generated an unprecedented 
volume of exome data for patients with CVMs, which have led to 
major advances toward defining the genetic basis of CVMs (34, 
35, 84, 85). This study used a phenotype nomenclature system 
based on the IPCCC (85). Meanwhile, a large-scale forward 
genetic screening approach using chemical mutagenesis in mice 
recently led to novel insights to the mechanisms driving abnormal 
cardiovascular development (86). Critically, this study undertook 
a detailed phenotyping approach using fetal echocardiography, 
postmortem 3D imaging, and histopathological evaluation of 
unprecedented scale. To illustrate the study’s scope, over 80,000 
mouse fetuses were scanned with fetal echocardiography, and 
over 200 mutant lines with CVMs were identified. The CVMs 
were classified according to the Mammalian Phenotype Ontology 
system but were also mapped to human phenotypes using the 
Fyler codes. The genetic and phenotype data generated from these 
two large-scale studies present seemingly unbounded opportuni-
ties for computational analyses. These include the opportunity to 
integrate cross-species phenotype data, which will have a key role 
in advancing understanding of disease pathogenesis (87). These 
data sets potentially represent the foundation onto which clinical 
genetic testing data and data from other research enterprises can 
be added using a uniform phenotyping language. There is the 
opportunity for the field of CV genetics to harmonize phenotype 
data with emerging standards used by large genotype–phenotype 
data sets within the broader field of genomics by mapping to 
the HPO. Given strong evidence that the genetic basis of non-
syndromic CVMs overlaps with neurodevelopmental and other 
non-cardiac anomalies (35), the integration with other domain-
specific genotype–phenotype data sets are likely to produce 
significant results.
At present, there are clear challenges to implementing the 
practices of phenomics into routine clinical interpretation of vari-
ants and genotype–phenotype research. Some of these challenges 
are ubiquitous, but others are unique to CVM phenotyping. Most 
are practical challenges that can be overcome through the efforts 
of highly motivated clinical and research programs. There is a 
clear need to adopt a standardized domain-specific CVM nomen-
clature where individual phenotypes are defined for every patient. 
Until a uniform nomenclature is adopted, phenotypes will have to 
be mapped between databases, which pose the risk for error and 
misclassification (88). On a clinical basis, the established variant 
databases, such as ClinVar, represent a great opportunity to begin 
to systematically adopt the reporting of deep phenotyping data. Of 
equal importance, molecular laboratories should start to require 
that detailed CVM phenotype data accompany genetic testing 
requests, which will help force improved clinical practices. These 
processes will be facilitated if caregivers treating patients with 
CVMs standardize clinical reporting practices in a manner that is 
both clinically practical and robust for data analysis. Harmonizing 
phenotype data across species will facilitate new discoveries. The 
development of high-throughput, quantitative methods for CVM 
phenotyping, such as automated digital analysis of imaging data, 
akin to facial image analysis, may speed discovery by breaking 
the bottleneck created by the highly specialized, labor-intensive 
nature of clinical CVM phenotyping (52, 89). While the resources 
required to advance CVM phenotyping are significant, these will 
be well worth the added investment to maximize the utility of 
currently funded genotyping projects. Of equal importance, the 
clinical interpretation of genetic testing will be improved with 
deep CVM phenotyping.
iNTeRPReTATiON OF GeNeTiC TeSTiNG
The tremendous effort in genomic and phenomic research has 
a direct effect on clinical testing. Clinical genetic testing moves 
rapidly to incorporate the most recent research results that have 
clinical utility and aid patient diagnosis or management. However, 
because this is an area of rapid accumulation of new data, clinical 
genetic testing results are not always straightforward since they 
represent a probability of causing or contributing to disease (90). 
There are two stages of interpretation of clinical genetic testing 
results. The clinical laboratory performs the first stage. Variants 
are classified, compared with ethnic and race-specific information 
in databases, analyzed using bioinformatic prediction programs, 
and classified into one of five categories: (1) benign, (2) likely 
benign, (3) VUS, (4) likely pathogenic, or (5) pathogenic (91). 
New guidelines have standardized and increased the stringency 
of interpretation, with more clear criteria for strength of evidence 
required for interpretation (91). Nevertheless, the interpretations 
provided for a given variant may differ between clinical genetic 
FiGURe 1 | Schematic outlining the clinical implementation of CvM genetic testing. (A) Deep phenotyping data include complete CVM diagnoses, 
congenital non-CV malformations, dysmorphic exam findings, neurodevelopmental abnormalities, and other pertinent medical history. Specification of relevant 
negative findings, including radiographic studies (e.g., head/renal ultrasound), neurodevelopmental evaluation, and specific cardiac evaluations, is important for 
robust datasets. Age that diagnoses were established or ruled out should be included. Phenotype data should be collected in a structured format (e.g., HPO). (B) 
Family history data are input as a three-generation pedigree, including documentation of relatives with negative cardiac screening. (C) Prior genetic testing results 
data include dates and testing laboratory. (D) Genetic testing decisions are patient, family, and disease differential specific. Current clinically available testing options 
include single gene (e.g., sequencing or deletion/duplication testing), multiple gene (e.g., NGS panels), or genome-wide (e.g., chromosomal analysis, CMA, or whole 
exome sequencing) testing. (e) Laboratory interpretation of genetic testing is based upon ACMG guidelines. High-quality patient data should be provided with the 
orders for genetic testing. (F) Clinical interpretation of genetic testing combines multidisciplinary CV genetics knowledge/expertise with the laboratory interpretation. 
(G) Direct clinical use includes providing results and counseling to family, reporting to health-care providers, recommending treatment, making appropriate 
subspecialty referrals, making appropriate plan for longitudinal monitoring, and instituting cascade genetic testing and/or family-based cardiac imaging as indicated. 
(H) Local database compiles high-quality phenotype and genotype data for multiple uses, including longitudinal follow up (e.g., completion of cardiac screening in 
family members or reassessment of variant interpretation), documentation of clinical practices and outcomes, and periodic data harvests for dissemination to public 
databases and peer-reviewed publication.
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testing laboratories. In addition, updates and revisions of the 
laboratory interpretation may occur as more information is 
obtained from larger cohorts. For this reason, families should also 
maintain a relationship with the CV genetics providers, as VUSs 
often get reclassified over time. A second stage is the interpreta-
tion provided by the clinician. Molecular testing results should 
be one piece of evidence in a diagnostic evaluation. These results 
need to be interpreted in the context of the patient’s medical his-
tory, physical exam findings, disease course, and family history 
to arrive at a diagnosis. Family history information and the seg-
regation of a potential disease-causing variant within the family 
may be important information to guide the clinical interpretation 
of the genetic testing results, especially in cases where novel 
genetic variants are identified. For CVMs, in which Mendelian 
inheritance may not be seen or decreased penetrance may make 
segregation with disease difficult to establish, there are increased 
challenges to the interpretation of genetic testing results.
A CVM genetic testing workflow begins with the ascertain-
ment of high-quality deep phenotype data (Figure 1). The genetic 
testing laboratory can improve their interpretation of genetic 
data when provided with clear phenotype information. The 
diagnostic interpretation of the clinical care team, longitudinal 
follow-up and outcome, and family-based clinical information 
and genetic testing results are all used by the testing laboratory 
to refine interpretation. Communicating the patient’s phenotype 
to the testing laboratory or clinical databases, such as ClinVar, 
is a critical step that is highly susceptible to errors, such as 
misclassifications or omissions. How can the genetics provider 
who orders genetic testing communicate the CVM phenotype 
accurately? The accuracy and completeness of the diagnosis may 
depend on the sources of the information, which include clinical 
notes, imaging study reports, procedure notes, or administrative 
diagnostic codes. The optimal source of this information likely 
depends on factors specific to patient and medical system. In 
order to minimize the errors, ideally the genetics provider must 
have access to all pertinent information (e.g., echocardiography 
reports, operative reports, cardiac catheterization reports), have 
sufficient background understanding and experience in CVM 
diagnoses to accurately define the patient’s CVM phenotype, 
and have a cardiologist readily available when clarifications are 
needed. While this process may be effectively conducted by 
a team of investigators devoted to a specific research project, 
undoubtedly in most pediatric cardiology centers, there are 
immense practical challenges to clinically implementing the above 
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scenario for every patient undergoing genetic testing. However, a 
multidisciplinary CV genetics program consisting of geneticists, 
cardiologists, genetic counselors, and molecular biologists, which 
fosters cross-disciplinary education and communication, is actu-
ally well suited to meet these needs. These collaborative groups 
of professionals improve the accuracy of the probabilistic genetic 
testing information and provide more expertise to the diagnosis 
and management of the patient.
There remain great opportunities for improving our ability to 
interpret the results of genetic variation and predicting impact. 
These are important priorities in all clinical fields that incorporate 
genetic testing into the diagnosis and management of patients. In 
the future, identification of genetic modifiers that contribute to 
phenotypic presentation and explain a portion of the variability 
and reduced penetrance in these disorders is necessary. This focus 
will need to include an improvement in our understanding of the 
impact of rare genetic variation in the population as well as the 
functional significance of common polymorphisms.
SUMMARY
In conclusion, there is strong evidence to support CMA testing as 
a first-line genetic test for infants with clinically significant CVMs. 
Molecular genetic testing with NGS panels is useful for the evalu-
ation of CVM patients in whom a specific genetic syndrome is 
suspected. In cases where genetic conditions are highly suspected 
but a specific syndrome is not recognized, WES may be indicated. 
NGS panels or WES may be diagnostic in multiplex families 
with CVMs. Data supporting the potential utility of expanded 
NGS CVM-gene panels or WES in isolated non-syndromic 
CVM patients are accumulating, but clinical sensitivity is cur-
rently unknown and conclusive variant interpretation remains 
problematic. Systems biology provides evidence that many CVM 
genes functionally converge on signaling and transcriptional 
pathways. Given these considerations, WES or whole genome 
sequencing will likely ultimately replace NGS panels. However, 
broader testing will result in ambiguous variant interpretation 
in CVM patients due in part to variable and expression and 
reduced penetrance. Incomplete phenotype information and lack 
of standardized methods for phenotyping also remain significant 
obstacles. Collaboration between genetics and cardiac care pro-
viders and molecular testing laboratories is needed to optimize 
variant interpretation. There are currently major opportunities to 
integrate and analyze molecular and phenotype data from human 
and animal research projects to advance our understanding of the 
cause of CVMs.
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